Revised 17 September 2026 · v1.8.0 · what changed

Every litre of petrol sold in India since the country hit its E20 target has one-fifth of its volume made up of something no refinery produced: ethanol, blended in at the pump-ready stage. That is not a demand forecast or an EV-adoption scenario playing out a decade from now — it is a structural, present-tense subtraction from the petrol pool refiners have to plan around today, and it lands on top of an ethanol distillation industry already running roughly 19.9 billion litres of annual capacity against an E20 requirement of around 11 billion litres, a surplus this blog has covered before. Indian refiners' answer has been to redirect capacity toward petrochemicals, and they are doing it at real scale — this blog has already quantified that pivot and the FCC-level engineering behind part of it. What hasn't happened yet, on the evidence available, is for that redirected capacity to reach the one downstream chain where India has the clearest, most quantified import problem: the naphtha- and olefin-derived chemistry that feeds pharmaceutical active ingredients, a chain still 43.45% dependent on China by import value.

1. What E20 actually removes from the refinery's petrol pool

The blending mandate does not reduce how much fuel Indians buy at the pump. It reduces how much of that fuel a refinery has to make. Ethanol enters the pool as a finished additive, not a refinery product, so the petrol-grade streams a refinery would otherwise maximise — reformate, isomerate, the straight-run and cracked naphtha fractions that make up the gasoline blend — are structurally in less demand per litre sold than they were before the mandate. This blog's earlier piece on the FCC (fluid catalytic cracking) lever put a number on how oversupplied the ethanol side already is: grain-based producers alone offered roughly 13,040 million litres against OMCs' stated ESY2025-26 requirement of about 10,500 million litres, and the industry-wide offer across grain and sugarcane feedstocks came to about 17,760 million litres — close to 1.7 times what the mandate needs. That oversupply is exactly why a move to E25 or beyond is being discussed at all, and every step in that direction frees more of the refinery's petrol-yield capacity for something else.

2. Where the freed capacity is actually going: a real, capital-backed pivot

Independent of the ethanol side, India's refiners have committed to a multi-year shift in what a barrel of crude is used for, and this blog has already tracked the national number: petrochemical intensity (PII) — the share of a refinery's output routed to petrochemical feedstock rather than fuels — has moved from roughly 7.7% to about 13% nationally, with individual refiners setting targets well above that average.

PII targets in percent; IOCL's PX-PTA unit at Paradip was ~95% complete by mid-2026, with the full cracker complex targeted for 2028–29. MRPL (Mangalore) has separately shelved a refinery capacity expansion to instead pursue its own petrochemical addition (the PACE project) — reported in trade press without capacity or cost figures firm enough to include in this table. IOCL's Barauni expansion (Section 7) also carries a downstream polypropylene unit alongside its refining-capacity add.

The pattern across most of these is the same: new capital is going into cracking and aromatics capacity that did not previously exist, not simply reconfiguring what refineries already had. That distinction matters for the naphtha-quality point below.

3. The chain that would matter for pharma, if the new capacity reached it

The textbook link between a refinery and a tablet runs through several hand-offs, not one. A steam cracker or catalytic reformer turns naphtha into the C1–C4 building blocks and BTX aromatics (benzene, toluene, xylenes); a separate layer of intermediate chemical producers converts those into key starting materials (KSMs); and API synthesisers turn the KSMs into the finished active ingredient. Four molecules illustrate why this particular chain, not fermentation-route bulk drugs, is the one worth watching for petrochemical-linked import substitution — and how differently import-dependent each already is:

• Paracetamol — 91% of India's paracetamol API imports come from China. Benzene is converted to nitrobenzene, which is hydrogenated to para-aminophenol (PAP) — industrially, either by catalytic hydrogenation of nitrobenzene directly (the Bamberger rearrangement route) or via a para-nitrochlorobenzene intermediate. Paracetamol itself is simply PAP acetylated with acetic acid. India's own demand for PAP runs around 40,000 tonnes a year — smaller than the roughly 110,000 tonnes of annual PAP capacity reported for Chinese producers alone, which is a scale gap a single new plant could plausibly close. Part of why Chinese supply stays attractive regardless: paracetamol API pricing has reportedly fallen from around ₹900/kg at pandemic-era highs to around ₹250/kg, undercutting the economics of a new domestic plant built against that price, not against the higher price that made the case for import substitution originally.
• Ibuprofen — 99.34% China-dependent in FY2023-24, improved to 80.73% by FY2024-25, with no PLI project behind the improvement at all. Propylene from a refinery's FCC or a steam cracker is used to alkylate benzene into isobutylbenzene (IBB), the actual KSM. From there, the original six-step Boots process (Friedel-Crafts acylation, Darzens condensation, then oxidation) yields ibuprofen at roughly 86% yield but poor atom economy; the newer BHC/Hoechst catalytic route does the same conversion in three steps. The same propylene stream that supplies IBB also supports isopropanol production — a solvent pharmaceutical manufacturing consumes in bulk, though not itself an ibuprofen precursor. This blog's earlier PIB-sourced Annexure analysis found ibuprofen's dependence dropped nearly 19 points in a single year with zero PLI capacity behind it — the sharpest improvement of any molecule in that dataset, and evidence private capacity can move this specific number without a subsidy, not proof the remaining 80.73% will close the same way.
• Diclofenac sodium — 72–80% import-dependent on China, by the same Shandong-KSM route as ibuprofen. A synthetic-route NSAID, not a fermentation product, and the closest thing on this list to a quantified, still-open target: dependency in that range but without a named PLI project against it.
• Aspirin (acetylsalicylic acid) — lower priority, because India already has a domestic base. Salicylic acid is made from phenol and CO2 via the Kolbe-Schmitt reaction, then acetylated to aspirin — the same petrochemical-phenol ancestry as paracetamol's PAP route. Unlike the other three, meaningful aspirin manufacturing already runs in India (Hyderabad, Gujarat) alongside China's Jiangsu and Zhejiang clusters, so this is not an obviously underserved target the way diclofenac and ibuprofen are.

The pattern holds across every fermentation-route molecule this piece could find a figure for: dependency is at or near total and largely flat year on year (Rifampicin 89.17%→89.01%, Ciprofloxacin 97.98%→98.02%), and the one PLI-funded exception (Penicillin G) still shows 95.8% import share despite being on the localisation list — being on the PLI's 28-molecule list has not reliably meant falling dependence, in this blog's own earlier reading of the same PIB Annexure. Ibuprofen complicates the synthetic-route picture in the opposite direction: its dependence fell sharply, 99.34% to 80.73% in a single year, with no PLI project behind that improvement at all — the sharpest single-year move in the dataset, achieved by market forces alone. That leaves diclofenac sodium as the more genuinely open target of the two petrochemical-route molecules this section named: still 72–80% dependent, no PLI project, and no documented market-driven improvement the way ibuprofen already has one. Aspirin (existing domestic base) and the near-total fermentation-route dependencies (a fermentation-capacity and technology-transfer constraint, not a naphtha or propylene one) remain lower priorities for the same reasons as before.

4. Where the geography for this already exists

One place the refinery and the pharma layer already sit inside the same industrial footprint is the Visakhapatnam–Kakinada Petroleum, Chemicals and Petrochemicals Investment Region (PCPIR) in Andhra Pradesh — at roughly 640 square kilometres, the largest of India's four PCPIRs. It already hosts HPCL's Visakhapatnam refinery alongside Hetero Drugs, one of India's largest API manufacturers, plus Coromandel Fertilizers and Andhra Petrochemicals. Andhra Pradesh is also one of the three states building a central government Bulk Drug Park under the Department of Pharmaceuticals' scheme — relocated in 2023 from its original Kakinada site to Nakkapalli in Anakapalli district, with roughly ₹1,877 crore committed to internal infrastructure. Nakkapalli sits in the same broader Uttarandhra industrial corridor as the PCPIR and the existing Jawaharlal Nehru Pharma City at nearby Parawada, rather than on the refinery's own fence line — proximity, not the pipeline hookup a true co-located KSM plant would need.

5. Why the chain hasn't actually rewired itself

Four separate constraints, not one, explain why freed refinery capacity has not visibly reached the API layer.

Naphtha specification. Naphtha is already a small but real share of India's major petroleum products by PPAC's own accounting — but PPAC's data also shows India still imports chemical-grade naphtha specifically, because domestic naphtha commonly isn't produced to the purity a cracker needs and gets burned as industrial fuel instead. Raising PII is a refining-configuration problem, not just a volume decision.

What the import-substitution scheme actually funded. The Bulk Drugs PLI (outlay ₹6,940cr) localised 28 molecules, including Penicillin G, Clavulanic Acid, Rifampicin and Atorvastatin — all fermentation-route bulk drugs, built on sugar or molasses feedstock, not the petrochemical/synthetic route paracetamol and ibuprofen represent. The scheme built to cut China dependence has not, on the public list, targeted the molecules this piece is about.

Economics at scale. China's PAP capacity alone is nearly three times India's total PAP demand, built by producers running at scale for two decades. A new Indian KSM plant competes against that pricing from day one, which is a harder problem than simply having naphtha or propylene nearby.

Where some of the freed naphtha is actually going: exports to China. DGCI&S bilateral trade data shows India's naphtha exports to China (light naphtha, HS 27101221, plus full-range naphtha, HS 27101229) had been flat-to-declining for two years — $1,865.4mn in FY2022-23, down to $1,123.9mn in FY2023-24, $1,207.1mn in FY2024-25 — then jumped to $2,425.0mn in FY2025-26, a 101% year-on-year increase. That reversal lands in the exact fiscal year this blog's own reporting confirms E20 blending took hold nationwide. The two facts don't prove causation on their own, but they are a specific, dated, testable coincidence: the same freed capacity Section 1 describes appears, at least in part, to be reaching China's own crackers as a raw feedstock export rather than a domestic KSM plant. That reframes this piece's core finding — it is not only that the freed capacity hasn't yet reached India's pharma-precursor chain; a rising share of it is being sold to the very country that chain is trying to depend on less.

6. What would actually have to be true

Closing this gap is not primarily a feedstock-availability question — the petrochemical capacity being built at Paradip, Ramayapatnam, Bina and Barmer is real and growing regardless of what happens to pharma. It is a question of whether any of that new naphtha and propylene gets refined to chemical grade and routed to a KSM plant built for the purpose, inside a scheme that actually targets synthetic-route molecules the way the Bulk Drugs PLI has targeted fermentation-route ones. If a next round of that scheme, or a state-level equivalent, wanted a short list rather than a blank slate, diclofenac sodium reads as the single most legible near-term target from Section 3 — synthetic, petrochemical-route, still 72–80% China-dependent, no PLI project, and with no market-driven improvement on record the way ibuprofen already has. Ibuprofen's own dependence has already fallen from 99.34% to 80.73% in a year without any government support, which argues for watching rather than subsidising it further; paracetamol's dependence is more total but also more scale-solvable, and aspirin already has a domestic production base. The Vizag-Kakinada PCPIR already has the closest thing to the right postcode in the country. Whether the pipeline gets built to match it is the open question this piece cannot yet answer with data, because as of this writing no public project names any of these molecules' KSM production as a target of the current build-out.

7. Upcoming refining capacity, beyond petrochemicals

The petrochemical build-out in Section 2 sits inside a larger, separate expansion of plain refining capacity. India's installed refining capacity stood at about 258.1 MMTPA in FY2024-25; credible estimates for 2030 range from roughly 295 MMTPA (Crisil Ratings, adding about 40 MT/800,000 bpd) to about 310 MMTPA depending on how many announced projects are counted as firm. Three individual projects stand out for how much of that they carry — and one of them, Barauni, is also a petrochemical project in its own right, since its scope includes a downstream polypropylene unit alongside the pure capacity add:

Panipat, Gujarat/Koyali and Barauni are IOCL's own three flagship expansions, and the company has said they take its group refining capacity from 80.8 to 98 MTPA once complete — per psuwatch's reporting on IOCL's Q1 numbers, not a figure this piece independently verified against IOCL's own filings.

Sources: PIB/MoPNG releases on the Ethanol Blended Petrol programme and the E20 mandate; this blog's own "India's Ethanol Surplus Isn't Going to Brazil or the USA," "The FCC Lever: Trading Petrol Yield for LPG," "The Barrel Really Is Shifting: India's Refiners Quantify the Petrochemical Pivot" and "India Cannot Sell ‘China-Free’ Medicine While Importing 43% of What's In It" (PIB-sourced China-dependence and Bulk Drugs PLI figures reused from that piece, not re-derived here); public reporting on IOCL, BPCL (including BORL/Bina, the proposed BPCL+Oil India JV and RRPCL/Ratnagiri), ONGC/OPaL and its Uttar Pradesh proposal, MRPL, Reliance Industries, Nayara and HPCL/HRRL petrochemical capex and PII targets (PIB, Business Standard, Oil & Gas Journal, ChemAnalyst-class trade press, environmentclearance.nic.in project filings, company project pages); this blog's own "Financing the Fuel-to-Chemicals Pivot," whose Panipat, Koyali, Reliance, BPCL+Oil India and ONGC figures were reused directly rather than re-derived, since they were more precisely sourced (company investor disclosures, PRNewswire) than what a fresh search surfaced for this piece; PIB and trade-press reporting (Oil & Gas Journal, psuwatch, Indian Infrastructure, PSU Connect, indiainvestmentgrid.gov.in) on Numaligarh's, Panipat's and Barauni's capacity expansions, used in place of a direct read of cht.gov.in and mopng.gov.in (both blocked from this session's network), and Crisil Ratings' 2030 national capacity estimate; Department of Pharmaceuticals and state-government material on the Andhra Pradesh Bulk Drug Park relocation to Nakkapalli; Gujarat PCPIR Authority and Andhra Pradesh PCPIR project material for site composition; published process literature on para-aminophenol, isobutylbenzene-route ibuprofen and Kolbe-Schmitt salicylic acid synthesis (patent filings, process-economics reviews) for the chemistry in Section 3; China-dependency figures for paracetamol (91%) and amoxicillin (89.9%) and the paracetamol API price series (₹900/kg to ₹250/kg) as reported in pharma-industry trade analysis (APIFDF Analytics, Policy Circle, Indrastra); the Ciprofloxacin (97.98%→98.02%), Rifampicin (89.17%→89.01%), Penicillin G (95.8%, single-year) and Ibuprofen (99.34%→80.73%) FY23-24/FY24-25 figures corrected against and reused from this blog's own "Five Years and ₹25,000 Crore Later, China Still Supplies Three-Quarters of India's Drug-Making Ingredients," whose 90-line PIB China-import Annexure (PRID 2237414, 10 Mar 2026) is the primary source -- this piece's first published version had used a less precise 99.6% ciprofloxacin figure and reported ibuprofen as unquantified, both corrected here after a cross-check against this blog's own archive; the 72–80% diclofenac sodium figure and the Shandong-KSM sourcing pattern for diclofenac as reported in industry commentary of uncertain primary-document backing, presented accordingly as directional rather than official. Figures on Chinese PAP capacity and India's PAP demand are as reported in secondary industry sources, not independently verified against a customs or company filing, and are presented as approximate. Naphtha-export-to-China figures (Section 5) are from DGCI&S TradeStat's Export → Country-wise-all-commodities report for China, HS 27101221 (light naphtha) and 27101229 (full-range naphtha), covering FY2022-23 through FY2025-26; each fiscal year's total was read directly from the report's own "Total" row rather than re-summed from individual HS lines, after an initial cross-check against published India-China aggregate trade figures caught a doubling error from summing that Total row a second time alongside the commodity rows it already covers.

Related on this blog

See also: India Exports the Naphtha and Benzene Its Own Pharma Industry Needs — Mostly to China — a standalone follow-up to Section 5's naphtha-export finding, extending it to benzene and isobutylbenzene · India's Ethanol Surplus Isn't Going to Brazil or the USA · The FCC Lever: Trading Petrol Yield for LPG · The Barrel Really Is Shifting: India's Refiners Quantify the Petrochemical Pivot · Financing the Fuel-to-Chemicals Pivot · India Cannot Sell “China-Free” Medicine While Importing 43% of What's In It · Five Years and ₹25,000 Crore Later, China Still Supplies Three-Quarters of India's Drug-Making Ingredients · India's Petrochemical Import Tree — From Petrol to Product.

About this article: Researched, written and edited by Umashankar Triplicane Dwarakanathan, with AI research assistance; every figure is meant to trace to the primary source cited. See the Editorial Policy for how sourcing, AI use and corrections work.